Postpartum Depression Medication Approved by Health Canada

Health Canada has authorized a new medication to treat postpartum depression, known as zuranolone, sold under the brand name Zurzuvae. This is the first drug approved in Canada specifically for this condition, which is recommended for moderate to severe postpartum depression.

Zuranolone is to be taken once daily for 14 days and is expected to be available in Canada by early 2026, pending coverage decisions by governments and insurers. Health Canada conducted a thorough review of Biogen's evidence, concluding that the drug meets all safety, effectiveness, and quality criteria.

Dr. Ryan Van Lieshout, a psychiatry professor at McMaster University, expressed hope that this approval will help reduce self-blame among those affected by postpartum depression, which affects approximately 23 percent of new mothers in Canada.

Unlike traditional antidepressants, zuranolone works faster with effects often seen within three days of treatment. In clinical trials, 27 percent of participants showed no depressive symptoms by day 15, with 57 percent of those treated experiencing significant improvements.

However, the drug is not recommended for pregnant or breastfeeding individuals and may cause significant sleepiness, leading to advisories against driving for 12 hours after taking it. Dr. Crystal Clark from the University of Toronto emphasized that treatment for postpartum depression should be tailored to the individual, highlighting that psychotherapy remains a first-line treatment.

The wholesale price in the U.S. for a 14-day treatment cycle is $15,900, although Canadian pricing has not yet been released. If you or someone you know is struggling, there are resources available for help.